References,Sample size,Interventions,Main race,Female (%),Mean HAMA,Mean age (Year),Attrition rate (%),Sponsor,Follow-up time (weeks),Diagnosis criteria
"Bidzan et al., 2012",301,vortioxetine: 5 mg/day,White,68.7,26.3,45.2,NA,"Takeda Pharmaceutical Company, Ltd.",8,dsm-iv-tr
"Bidzan et al., 2012",301,placebo,White,61.6,26.8,45.3,NA,"Takeda Pharmaceutical Company, Ltd.",8,dsm-iv-tr
